Lipids & metabolic liver disease
Rising burden of metabolic dysfunction-associated steatotic liver disease in adolescents aged 15–19 years and projections to 2035
Authors' conclusion
The prevalence of MASLD among adolescents continues to rise. Multiple disparities are apparent, with a rapid rise of MASLD in adolescents in Europe and among females. These data may have important implications for shaping public health policies and clinical practice.
Study context
- Population
- Adolescents aged 15–19 years across 204 countries/territories, 2010 to 2021
- Outcome
- Global prevalence of MASLD among adolescents
- Follow-up
- 2021
Methodological details204 countries/territories, 2010–2021 temporal trends, autoregressive integrated moving average projections to 2035
- 204 countries/territories
- 2010–2021 temporal trends
- Autoregressive integrated moving average projections to 2035
Main finding
As reported in the abstract
Global prevalence
5.31 %
95% UI 4.06--6.78
Relative increase in global prevalence, 2010 to 2021
6.77 %
Further findings
Regional prevalence of MASLD
%
- Southeast Asia (lowest)
- 4.53 (3.47-5.80)
- Eastern Mediterranean region (highest)
- 8.80 (6.79-11.04)
- Steepest relative increase: High-middle sociodemographic index countries
- +11.22
Sex-stratified MASLD prevalence
- Baseline prevalence, males
- 5.94 % [4.53-7.56]
- Baseline prevalence, females
- 4.64 % [3.55-5.91]
- Increase in prevalence 2010 to 2021, females vs males
- +8.72 % vs. + 5.31 %
- Projected rise by 2035, females vs males
- 10.3 % vs. 6.4 %
High BMI and MASLD prevalence
- High BMI correlated with MASLD prevalence
- P < 0.001
Original publication
Rising burden of metabolic dysfunction-associated steatotic liver disease in adolescents aged 15–19 years and projections to 2035. Diabetes Res Clin Pract. Published 17 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →